{"id":780958,"date":"2023-08-30T09:59:43","date_gmt":"2023-08-30T13:59:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"modified":"2023-08-30T09:59:43","modified_gmt":"2023-08-30T13:59:43","slug":"effector-therapeutics-to-participate-in-upcoming-investor-conferences-5","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","title":{"rendered":"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug.  30, 2023  (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced that the management team will participate in and host 1&#215;1 meetings at the following upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt;margin-bottom:12pt\">Presentation at the H.C. Wainwright 25th Annual Global Investment Conference on September 13 at 10AM ET<\/li>\n<li style=\"margin-top:12pt;margin-bottom:12pt\">Fireside chat at the 2023 Cantor Global Healthcare Conference on September 26 at 3PM ET<\/li>\n<\/ul>\n<p>A live webcast of both events will be available on the &#8220;Events and Presentations&#8221; page of the Investors section of the Company\u2019s website with a replay available for 30 days following the event. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DXiPewTWHDy-GQoHWmtFuGkFRI7KkuGhJ6L5GrYrV7eCFGpZmhXfN69WabpqKGMmhMWp2SHfLaHHOnuMqxJrPvhJS6kgd7qjRR8_eCCUZFY=\" rel=\"nofollow noopener\" target=\"_blank\">investors.effec<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=z7N2yJ0Hrp2D5T36UXJsY3es-ezmecx4e8eJnKakZSO2cP5LHD5BUh0CTiPYRI-icnCEBtADkSVvy_iL19h3fg==\" rel=\"nofollow noopener\" target=\"_blank\">t<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UIpIGhw5ZL6-SHmi9gXLjWajpYYYcwVlSmnhIzflfjrOcBE_GaQKnCEt4HSARpBEZF3cuNoTQMM2VFkZsKbg5A==\" rel=\"nofollow noopener\" target=\"_blank\">or.com<\/a>.<\/p>\n<p>\n        <strong>About eFFECTOR Therapeutics<\/strong>\n      <\/p>\n<p>eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs. eFFECTOR\u2019s STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK). The eIF4F complex is a central node where two of the most frequently mutated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge to activate the translation of select mRNA into proteins that are frequent culprits in key disease-driving processes. Each of eFFECTOR\u2019s product candidates is designed to act on a single protein that drives the expression of a network of functionally related proteins, including oncoproteins and immunosuppressive proteins in T cells, that together control tumor growth, survival and immune evasion. eFFECTOR\u2019s lead product candidate, tomivosertib, is a MNK inhibitor currently being evaluated in KICKSTART, a randomized, double-blind, placebo-controlled Phase 2b trial of tomivosertib in combination with pembrolizumab in patients with metastatic non-small cell lung cancer (NSCLC). Zotatifin, eFFECTOR\u2019s inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC. eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Investors:<\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">\n            <strong>Media:<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Christopher M. Calabrese<br \/>Managing Director<br \/>LifeSci Advisors<br \/>917-680-5608<br \/><a href=\"mailto:ccalabrese@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">ccalabrese@lifesciadvisors.com<\/a><\/td>\n<td style=\"vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">Kevin Gardner<br \/>Managing Director<br \/>LifeSci Advisors<br \/>617-283-2856<br \/><a href=\"mailto:kgardner@lifesciadvisors.com\" rel=\"nofollow noopener\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/td>\n<td style=\"vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"vertical-align: top\">Mike Tattory<br \/>Account Supervisor<br \/>LifeSci Communications<br \/>609-802-6265<br \/><a href=\"mailto:mtattory@lifescicomms.com\" rel=\"nofollow noopener\" target=\"_blank\">mtattory@lifescicomms.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTBlNzMyZjAtYWVhZS00OWE4LTk5YjUtNDFjZGZmODkxOTI1LTEwOTQwODI=\/tiny\/eFFECTOR-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced that the management team will participate in and host 1&#215;1 meetings at the following upcoming investor conferences: Presentation at the H.C. Wainwright 25th Annual Global Investment Conference on September 13 at 10AM ET Fireside chat at the 2023 Cantor Global Healthcare Conference on September 26 at 3PM ET A live webcast of both events will be available on the &#8220;Events and Presentations&#8221; page of the Investors section of the Company\u2019s website with a replay available for 30 days following the event. For more information, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-780958","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced that the management team will participate in and host 1&#215;1 meetings at the following upcoming investor conferences: Presentation at the H.C. Wainwright 25th Annual Global Investment Conference on September 13 at 10AM ET Fireside chat at the 2023 Cantor Global Healthcare Conference on September 26 at 3PM ET A live webcast of both events will be available on the &#8220;Events and Presentations&#8221; page of the Investors section of the Company\u2019s website with a replay available for 30 days following the event. For more information, &hellip; Continue reading &quot;eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-30T13:59:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2023-08-30T13:59:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"},\"wordCount\":371,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\",\"name\":\"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=\",\"datePublished\":\"2023-08-30T13:59:43+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","og_locale":"en_US","og_type":"article","og_title":"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) &#8212; eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (\u201cSTRIs\u201d) for the treatment of cancer, today announced that the management team will participate in and host 1&#215;1 meetings at the following upcoming investor conferences: Presentation at the H.C. Wainwright 25th Annual Global Investment Conference on September 13 at 10AM ET Fireside chat at the 2023 Cantor Global Healthcare Conference on September 26 at 3PM ET A live webcast of both events will be available on the &#8220;Events and Presentations&#8221; page of the Investors section of the Company\u2019s website with a replay available for 30 days following the event. For more information, &hellip; Continue reading \"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-30T13:59:43+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2023-08-30T13:59:43+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"},"wordCount":371,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/","name":"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=","datePublished":"2023-08-30T13:59:43+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxMzEzNiM1Nzg5MDYyIzIwODI1MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/effector-therapeutics-to-participate-in-upcoming-investor-conferences-5\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780958","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=780958"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/780958\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=780958"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=780958"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=780958"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}